Gunzburg: clinical trials of a single influenza and coronavirus vaccine to begin at the end of 2022

by time news

A technological platform has been created in Russia, on the basis of which it is possible to create a single vaccine against influenza and coronavirus. Its tests will begin at the end of next year, the director of the Center. N.F. Gamalei Alexander Gunzburg.

The technology platform is based on a hybrid rotavirus vaccine, he said. At the same time, a drug is being developed against various variants of the coronavirus.

“If everything goes well with this platform, it is this technology that works, then we will move on to a more complex option – combining influenza hemagglutinin antigens and, accordingly, coronavirus S-proteins in one vaccine. Clinical trials of the new drug will start at the end of next year, ”said Mr Gunzburg.

In Russia, several vaccines are already being created at once, which simultaneously protect against influenza and coronavirus. Earlier it was reported that the state corporation “Rostec” plans to register such a drug by the beginning of 2022. According to the head of the Ministry of Industry and Trade Denis Manturov, the first results of the development will appear before the end of the year. Also, the A.A. Smorodintsev Research Institute of Influenza of the Ministry of Health is engaged in the creation of a double-acting vaccine. The Chumakov Center conducted a study on the combination of the CoviVac coronavirus vaccine and the influenza vaccine in animals. According to the director of the center, as a result, a “significant antibody response” was obtained.

For information on how vaccinations against influenza and COVID-19 are combined, read the article “Kommersant” “You do not need to enter anyway.”

.

You may also like

Leave a Comment